N-Zyme Biotec

Executive Summary

N-Zyme Biotec is a private, clinical-stage biotech company based in San Diego, California, dedicated to developing the first targeted pepsin inhibitor for laryngopharyngeal reflux (LPR). By repurposing and reformulating the HIV protease inhibitor fosamprenavir, the company aims to address a significant unmet medical need in reflux diseases. LPR affects millions globally, yet no FDA-approved therapies specifically target the underlying pathophysiology involving pepsin. N-Zyme's approach leverages a well-characterized molecule with a known safety profile, potentially accelerating development and reducing risk. The company is advancing two formulations: a sustained-release oral tablet for systemic delivery and a dry powder inhaler for localized airway administration, targeting different patient populations and disease manifestations. Both formulations are designed to inhibit pepsin activity, thereby reducing tissue damage and symptoms associated with LPR. As a clinical-stage entity, N-Zyme's near-term value hinges on successful clinical execution and regulatory progress. The company has not disclosed specific trial timelines, but given the repurposing strategy, it may have already completed preclinical studies and early-phase safety trials. Key upcoming catalysts include the initiation of Phase 2 efficacy trials for the oral formulation and potential IND clearance for the inhaler. The private nature of the company means that significant value inflection points could also come from strategic partnerships, licensing deals, or additional financing. While the technology offers a novel approach in a large market, execution risk remains moderate due to the early stage and the competitive landscape in reflux therapeutics.

Upcoming Catalysts (preview)

• Q2 2026Phase 2 clinical trial initiation for oral fosamprenavir formulation60% success
• H2 2026FDA IND acceptance for dry powder inhaler formulation50% success